Veru reports FY2022 net loss $83.8M; sabizabulin EUA faces FDA advisory panel 8-5 vote against

VERU INC.

Full-year net loss $83.8M ($1.05 diluted EPS) vs net income $7.4M in FY2021.
Total net revenues fell to $39.4M from $61.3M; FC2 product sales decline cited.
R&D spending surged to $70.6M from $32.7M on sabizabulin and oncology programs.
FDA advisory committee voted 8-5 against sabizabulin EUA; final FDA decision pending.
Cash and equivalents $80.2M at Sept. 30, 2022, down from $122.4M a year earlier.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.7

VERU INC. reported financial results for fiscal 2022 fourth quarter and full year ended September 30, 2022.

Period: fiscal 2022 fourth quarter and full year ended September 30, 2022
Result: reported results

Exact text from the filing

Veru Inc. (NASDAQ: VERU), a biopharmaceutical company focused on developing novel medicines for COVID-19 and other viral ARDS-related diseases and for oncology, today announced financial results for its fiscal 2022 fourth quarter and full year ended September 30, 2022 and provided a business update.

View on SEC.gov

20 earnings releases filed in the last 30 days. Browse all earnings releases →

VERU INC. filing history →

Source: SEC EDGAR

accession 0001193125-22-297978

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.